share_log

Novavax | 8-K: Settlement Agreement

Novavax | 8-K: Settlement Agreement

諾瓦瓦克斯醫藥 | 8-K:和解協議
美股SEC公告 ·  2024/11/06 06:06

Moomoo AI 已提取核心訊息

Novavax has entered into a Termination and Settlement Agreement with the UK Health Security Agency on November 1, 2024, resolving disputes related to their COVID-19 vaccine supply agreement. The settlement requires Novavax to refund $123.8 million to the UK authority, which includes $11.3 million in interest provisions.The repayment will be structured in equal quarterly installments of $10.3 million over three years, ending June 30, 2027, with the first payment due on November 30, 2024. The company has the option to accelerate payments to avoid interest charges. The agreement effectively terminates the previously amended vaccine supply agreement from July 2022 and releases both parties from all related claims.
Novavax has entered into a Termination and Settlement Agreement with the UK Health Security Agency on November 1, 2024, resolving disputes related to their COVID-19 vaccine supply agreement. The settlement requires Novavax to refund $123.8 million to the UK authority, which includes $11.3 million in interest provisions.The repayment will be structured in equal quarterly installments of $10.3 million over three years, ending June 30, 2027, with the first payment due on November 30, 2024. The company has the option to accelerate payments to avoid interest charges. The agreement effectively terminates the previously amended vaccine supply agreement from July 2022 and releases both parties from all related claims.
諾瓦瓦克斯醫藥於2024年11月1日與英國公共衛生安全局簽署了終止和和解協議,解決了與其COVID-19生物-疫苗供應協議相關的爭議。和解要求諾瓦瓦克斯醫藥向英國當局退還12380萬美元,其中包括1130萬美元的利息條款。還款將分爲三年內的等額季度分期付款,每期1030萬美元,至2027年6月30日結束,首期付款到期日爲2024年11月30日。公司有選項加速付款以避免利息費用。該協議有效終止了2022年7月修訂的生物-疫苗供應協議,解除雙方所涉及的所有相關索賠。
諾瓦瓦克斯醫藥於2024年11月1日與英國公共衛生安全局簽署了終止和和解協議,解決了與其COVID-19生物-疫苗供應協議相關的爭議。和解要求諾瓦瓦克斯醫藥向英國當局退還12380萬美元,其中包括1130萬美元的利息條款。還款將分爲三年內的等額季度分期付款,每期1030萬美元,至2027年6月30日結束,首期付款到期日爲2024年11月30日。公司有選項加速付款以避免利息費用。該協議有效終止了2022年7月修訂的生物-疫苗供應協議,解除雙方所涉及的所有相關索賠。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息